Should You Buy Scotts Miracle-Gro in May?
Yes, if you think that cannabis legalization is coming soon to the U.S.
The marijuana industry is expected to triple in the next five years -- and many investors are looking to profit. As states and entire countries decriminalize or legalize cannabis and/or its components, there are loads of opportunities for entrepreneurs and existing companies.
But as in any nascent industry, there are also loads of risks and bad actors. Whether you're a first-time investor or a seasoned veteran, it pays to understand all of the moving parts. This guide will get you up to speed quickly, and we'll share a couple of the marijuana companies that we watch closely.
|Green Thumb Industries (OTC:GTBIF)||Marijuana grower and retailer|
|Trulieve Cannabis (OTC:TCNNF)||Marijuana grower and retailer|
|Innovative Industrial Properties (NYSE:IIPR)||Ancillary provider|
|GrowGeneration (NASDAQ:GRWG)||Ancillary provider|
|Scotts Miracle-Gro (NYSE:SMG)||Ancillary provider|
|GW Pharmaceuticals (NASDAQ:GWPH)||Biotech|
Source: Yahoo Finance.
Green Thumb Industries (OTC:GTBIF) benefited from tremendous growth in its home state of Illinois throughout much of 2020. Illinois’ legal adult-use recreational marijuana market opened for business at the beginning of the year.
The company owns retail cannabis stores in 12 states across the U.S. and operates 13 manufacturing facilities. Green Thumb holds licenses for 96 retail cannabis locations but has opened only a little over half that many stores. That, along with the opportunity to expand into additional states (especially New Jersey, with its new recreational marijuana market), gives the company a significant growth runway.
The cannabis grower and retailer has been consistently profitable since 2017, an achievement few other marijuana companies can claim. Its sales and earnings continue to soar. Trulieve’s next big growth opportunity is in Massachusetts, where it expects to enter the state’s recreational marijuana market in 2021.
There’s one big downside to marijuana being illegal at the federal level in the U.S.: Cannabis companies can’t easily secure capital from banks or financial institutions. However, that creates a big opportunity for Innovative Industrial Properties (NYSE:IIPR), which buys properties from U.S. medical cannabis operators and then leases the properties back to them. This gives the cannabis operator much-needed cash. And being in the landlord business gives IIP a steady revenue stream.
The COVID-19 pandemic disrupted IIP’s business a little, though, with three tenants receiving temporary rent deferrals due to coronavirus-related financial headwinds. But the company has still been able to deliver phenomenal growth during the pandemic. It’s highly profitable. Also, because the company is organized as a real estate investment trust (REIT), IIP must return at least 90% of its taxable income to shareholders in the form of dividends.
The booming U.S. cannabis industry has created a fast-growing market for supplies for hydroponics (growing plants without soil in liquid nutrient solutions) and organic gardening. GrowGeneration (NASDAQ:GRWG) is the largest specialty retail chain focused on this market.
While much of GrowGeneration’s business is catering to cannabis growers, the company also sells to other types of gardeners. GrowGeneration has seen a surge in customers who have jumped into organic gardening at home due to the COVID-19 pandemic.
Scotts Miracle-Gro (NYSE:SMG) is another company benefiting from the same trends that have boosted GrowGeneration’s sales. The company’s Hawthorne Gardening subsidiary ranks as a leading supplier of hydroponic gardening products to the cannabis industry.
Although Hawthorne is the primary growth driver for Scotts, the company still makes well over half of its total revenue from sales of its consumer lawn and garden products. This business has also benefited from the COVID-19 pandemic.
In 2018, GW Pharmaceuticals' (NASDAQ:GWPH) Epidiolex became the first drug made from a cannabis plant to be approved by the U.S. Food and Drug Administration (FDA). Sales of Epidiolex routinely surpassed expectations in its initial approved indications, treating Dravet syndrome and Lennox-Gastaut syndrome, both of which are rare forms of childhood epilepsy. The cannabis-focused biotech saw new patient starts for Epidiolex slow slightly with the COVID-19 pandemic, but it continued to deliver strong revenue growth.
In August 2020, GW won FDA approval for Epidiolex in treating tuberous sclerosis complex (TSC), a rare disease whereby benign tumors grow in vital body organs. This opens up a significant new market to the company, as around 50,000 people in the U.S. and roughly 1 million people worldwide have the disease.
Let’s first cover some of the most important things you need to know to get started with investing in marijuana stocks:
1. There are three broad categories of marijuana stocks.
2. There are two primary cannabis markets.
3. Geography is tremendously important.
The COVID-19 pandemic has affected nearly every part of the global economy, including the cannabis industry. In many U.S. states, cannabis dispensaries have been designated as essential businesses. Cannabis sales boomed in some states during the first few months of the coronavirus outbreak as people sought ways to cope with the anxiety caused by lockdowns and the resulting economic chaos.
This trend boosted business for marijuana growers and retailers serving these states. It also helped ancillary providers supplying gardening and other products to these companies.
However, some cannabis companies were hit hard by the pandemic. For example, recreational cannabis retailers in tourist destinations such as Las Vegas saw their customer traffic dwindle as people avoided travel. Some of these companies started focusing on home delivery to generate revenue.
The top cannabis-focused biotech experienced challenges promoting its products to healthcare professionals. Many sales calls had to be conducted virtually, and new patient starts slipped as people delayed doctor visits.
We just went step-by-step through how to invest in cannabis, but just because there's a trendy new sector with lots of press and potential growth doesn't mean you need to put your hard-earned money in it. After all, if you buy broad index funds, you're covered no matter what sector of the stock market does well.
Think through the pros and cons as you read on: Should You Invest in Marijuana Stocks?
Yes, if you think that cannabis legalization is coming soon to the U.S.
With potential renovations, the company's total investment could hit nearly $68 million.
The company slid an announcement concerning a new share offering at the bottom of its quarterly financial report.
ACB earnings call for the period ending March 31, 2021.
Still, it managed that rarest of all things for marijuana companies: a net profit.
It's good news for marijuana legalization -- but bad news for cannabis stocks.
The company's expansion in its home state served as the primary growth driver in the first quarter.
These two unstoppable companies can help your portfolio ride out another market crash or correction.
The company recently posted earnings, and its revenue just keeps climbing.
This pure-play cannabis company is prepared for another successful year.